[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

3 Dividend Aristocrats Under $100 to Buy and Hold Forever

Imagine buying Apple back in the 1980s, when a share cost around 10 cents on a split-adjusted basis. Stories like that are why investors still seek affordable, high-quality investments under $100 that have the potential to skyrocket in the next few decades. 

However, price alone does not make a stock worth buying, and not every sub-$100 stock becomes the next Apple or Nvidia. 

Fundamentals

See More
  • Market Capitalization, $K 147,130,944
  • Shares Outstanding, K 1,741,813
  • Annual Sales, $ 44,328 M
  • Annual Income, $ 6,524 M
  • EBIT $ 9,389 M
  • EBITDA $ 12,505 M
  • 60-Month Beta 0.65
  • Price/Sales 3.34
  • Price/Cash Flow 12.15
  • Price/Book 2.81

Options Overview Details

View History
  • Implied Volatility 30.49% (+1.56%)
  • Historical Volatility 31.36%
  • IV Percentile 92%
  • IV Rank 78.14%
  • IV High 34.27% on 03/27/26
  • IV Low 16.97% on 08/12/25
  • Expected Move (DTE 4) 2.20 (2.50%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 27,495
  • Volume Avg (30-Day) 23,207
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 228,332
  • Open Int (30-Day) 217,951
  • Expected Range 85.71 to 90.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.28
  • Number of Estimates 7
  • High Estimate $1.28
  • Low Estimate $1.27
  • Prior Year $1.26
  • Growth Rate Est. (year over year) +1.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.97 +7.25%
on 05/11/26
97.32 -9.67%
on 04/20/26
-8.90 (-9.19%)
since 04/17/26
3-Month
81.97 +7.25%
on 05/11/26
116.82 -24.74%
on 02/27/26
-25.38 (-22.40%)
since 02/18/26
52-Week
81.97 +7.25%
on 05/11/26
139.06 -36.78%
on 06/24/25
-46.89 (-34.78%)
since 05/16/25

Most Recent Stories

More News
3 Dividend Aristocrats Under $100 to Buy and Hold Forever

These three Dividend Aristocrats under $100 offer steady payouts, reasonable payout ratios, and analyst-backed upside potential.

ABT : 87.91 (+4.07%)
MKC : 46.70 (+0.76%)
SJM : 103.64 (+3.08%)
MDT : 77.32 (+1.54%)
Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell

See the recent insider activity surrounding Okta, Micron Technology, and Abbott Laboratories, and what these moves signal to investors.

ABT : 87.91 (+4.07%)
MU : 681.54 (-5.95%)
OKTA : 87.04 (+5.16%)
Sell in May and Go Away—Starting With These 3 Stocks

Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.

MSFT : 423.54 (+0.38%)
META : 611.21 (-0.49%)
GOOGL : 396.94 (+0.04%)
ABT : 87.91 (+4.07%)
CL : 89.92 (+2.03%)
ORCL : 186.61 (-3.29%)
DXCM : 65.09 (+5.61%)
BKH : 73.98 (+1.57%)
AMZN : 264.86 (+0.27%)
Abbott Laboratories Stock: Analyst Estimates & Ratings

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

ABT : 87.91 (+4.07%)
XLV : 145.72 (+0.43%)
$SPX : 7,403.05 (-0.07%)
Wall Street Is High on These 3 Dividend Aristocrats

We take a look at three top-rated companies that have raised their dividends without interruption for decades.

LIN : 510.86 (+0.94%)
TGT : 123.40 (+1.53%)
ABT : 87.91 (+4.07%)
WMT : 133.34 (+1.44%)
Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up Shares of This Blue-Chip Dividend Payer

Abbott’s business and dividend story remain intact even as the stock trades near 52‑week lows.

ABT : 87.91 (+4.07%)
$SPX : 7,403.05 (-0.07%)
$SRHC : 1,695.90 (+0.42%)
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie's early 2026 price pullback is an irresistable opportunity for buy-and-hold investors looking for income and compounding opportunities.

ABT : 87.91 (+4.07%)
ABBV : 209.41 (-0.47%)
Abbott receives FDA clearance and CE Mark for next-generation Ultreonâ„¢ 3.0 AI-powered coronary imaging platform

ABBOTT PARK, Ill. , April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreonâ„¢...

ABT : 87.91 (+4.07%)
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

ABBOTT PARK, Ill. , April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation...

ABT : 87.91 (+4.07%)
This Boring Dividend King Might Be the Safest Pick to Add to Your Portfolio

Abbott Labs is a balance of income and growth.

ABT : 87.91 (+4.07%)
$SPX : 7,403.05 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures...

See More

Key Turning Points

3rd Resistance Point 92.61
2nd Resistance Point 90.26
1st Resistance Point 89.09
Last Price 87.91
1st Support Level 85.57
2nd Support Level 83.22
3rd Support Level 82.05

See More

52-Week High 139.06
Fibonacci 61.8% 117.25
Fibonacci 50% 110.51
Fibonacci 38.2% 103.78
Last Price 87.91
52-Week Low 81.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.